These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 26888024)

  • 1. The safety of incretin based drug treatments for type 2 diabetes.
    Bolen SD; Maruthur NM
    BMJ; 2016 Feb; 352():i801. PubMed ID: 26888024
    [No Abstract]   [Full Text] [Related]  

  • 2. The safety of incretin based drugs.
    Montori VM
    BMJ; 2014 Apr; 348():g2779. PubMed ID: 24764568
    [No Abstract]   [Full Text] [Related]  

  • 3. Incretin-based glucose-lowering medications and the risk of acute pancreatitis and/or pancreatic cancer: Reassuring data from cardio-vascular outcome trials.
    Nauck MA; Meier JJ; Schmidt WE
    Diabetes Obes Metab; 2017 Sep; 19(9):1327-1328. PubMed ID: 28432752
    [No Abstract]   [Full Text] [Related]  

  • 4. ACP Journal Club. Incretin use was not associated with increased risk for acute pancreatitis.
    Schectman J
    Ann Intern Med; 2015 Jun; 162(12):JC12. PubMed ID: 26075777
    [No Abstract]   [Full Text] [Related]  

  • 5. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
    Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
    BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiovascular safety of incretin-based antidiabetic treatment - results of completed clinical trials].
    Jermendy G
    Orv Hetil; 2016 Apr; 157(16):603-10. PubMed ID: 27063427
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Smits MM; Muskiet MH; Tonneijck L; van Raalte DH
    Diabetes Care; 2015 Jul; 38(7):e106-7. PubMed ID: 26106231
    [No Abstract]   [Full Text] [Related]  

  • 8. Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?
    Olansky L
    Cleve Clin J Med; 2010 Aug; 77(8):503-5. PubMed ID: 20682512
    [No Abstract]   [Full Text] [Related]  

  • 9. Response to Comment on Thomsen et al. Incretin-Based Therapy and Risk of Acute Pancreatitis: A Nationwide Population-Based Case-Control Study. Diabetes Care 2015;38:1089-1098.
    Thomsen RW; Pedersen L; Møller N; Kahlert J; Beck-Nielsen H; Sørensen HT
    Diabetes Care; 2015 Jul; 38(7):e108-9. PubMed ID: 26106232
    [No Abstract]   [Full Text] [Related]  

  • 10. Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials.
    Roshanov PS; Dennis BB
    Diabetes Res Clin Pract; 2015 Dec; 110(3):e13-7. PubMed ID: 26643128
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based therapies and risk of pancreatic cancer in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.
    Wang H; Liu Y; Tian Q; Yang J; Lu R; Zhan S; Haukka J; Hong T
    Diabetes Obes Metab; 2018 Apr; 20(4):910-920. PubMed ID: 29193572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Preying on the pancreas? Scientists debate whether newer diabetes medications do harm.
    Berg EG
    Diabetes Forecast; 2013 Oct; 66(10):26, 28, 30-1. PubMed ID: 24224353
    [No Abstract]   [Full Text] [Related]  

  • 13. Incretin-based drugs and the risk of congestive heart failure.
    Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
    Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and benefit of incretin-based therapies in patients with type 2 diabetes: learnings and reflections.
    Rizvi AA; Linhart A; Vrablik M; Liberopoulos E; Rizzo M
    Expert Opin Drug Saf; 2022 Mar; 21(3):291-293. PubMed ID: 35188012
    [No Abstract]   [Full Text] [Related]  

  • 15. No increased heart failure risk is reported with DPP-4 inhibitors.
    Wise J
    BMJ; 2016 Apr; 353():i2363. PubMed ID: 27118534
    [No Abstract]   [Full Text] [Related]  

  • 16. Pooled patient level data are better suited than study level data to investigate the link between dipeptidyl peptidase-4 inhibitors and the risk of heart failure in type 2 diabetes.
    Patel T; Tesfaldet B; Gandotra C;
    BMJ; 2016 May; 353():i2920. PubMed ID: 27220716
    [No Abstract]   [Full Text] [Related]  

  • 17. Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
    Egan AG; Blind E; Dunder K; de Graeff PA; Hummer BT; Bourcier T; Rosebraugh C
    N Engl J Med; 2014 Feb; 370(9):794-7. PubMed ID: 24571751
    [No Abstract]   [Full Text] [Related]  

  • 18. Incretin-based pharmacotherapy and risk of adverse pancreatic events in the ethnic Chinese with diabetes mellitus: A population-based study in Taiwan.
    Tseng CM; Liao WC; Chang CY; Lee CT; Tseng CH; Hsu YC; Lin JT
    Pancreatology; 2017; 17(1):76-82. PubMed ID: 27743712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
    Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
    Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pro- or anti-inflammatory properties of the adipokine dipeptidyl peptidase-4?
    Xu L; Spinas GA; Niessen M
    Gastroenterology; 2011 Dec; 141(6):e17. PubMed ID: 22036848
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.